The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer & Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.
Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.
The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.
The firm also believes that due to the size of this acquisition, the company is likely to "cap out" its ability to continue to acquire in Germany.
Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.
Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。